Research programme: autoimmune therapies - Genten Therapeutics/Intrexon

Drug Profile

Research programme: autoimmune therapies - Genten Therapeutics/Intrexon

Latest Information Update: 28 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genten Therapeutics
  • Developer Genten Therapeutics; Intrexon Corporation
  • Class Anti-inflammatories; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Coeliac disease

Most Recent Events

  • 28 Sep 2016 Early research in Coeliac disease in USA (unspecified route)
  • 23 Sep 2016 Intrexon corporation enters into Exclusive Channel Collaborations (ECC) with Genten Therapeutics to develop peptides for Coeliac disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top